Agilent Technologies Inc NYSE:A Price, Chart, News & Insight

Agilent Expands Hematologic Cancer Profiling Portfolio with New Pan Heme NGS Solution

Agilent Technologies (NYSE: A) launched SureSelect Cancer Research Pan Heme, a new next-generation sequencing research solution designed for comprehensive genomic profiling of hematologic malignancies.

Developed with Roswell Park Comprehensive Cancer Center, the platform combines DNA and RNA profiling with automated sample preparation and integrated bioinformatics. It is designed to streamline molecular profiling workflows for blood cancers while reducing hands-on laboratory work.

SureSelect Cancer Research Pan Heme analyzes 359 DNA genes and 124 RNA genes and can assess several major genomic alteration classes, including single-nucleotide variants, insertions and deletions, copy-number variants, immunoglobulin translocations and gene fusions.

Agilent said Roswell Park’s current implementation of the integrated laboratory and informatics workflow can generate sample-to-report results in approximately 48 hours.

The system can also be paired with Agilent’s Magnis NGS Prep System for automated library preparation and target enrichment, while QIAGEN Clinical Insight supports variant analysis and reporting. Manual and semi-automated configurations are available for laboratories with different throughput requirements.

The launch expands Agilent’s cancer research portfolio alongside SureSelect Cancer Research CGP for solid tumors and SureSelect Human All Exon V8 for broader genomic profiling.

SureSelect Cancer Research Pan Heme is intended for research use only and is not approved for diagnostic procedures.

💬

WS Investor 11-10-26

Agilent Expands Oligonucleotide Manufacturing Capacity With New Boulder Lab

Agilent Technologies (NYSE: A) announced the opening of additional laboratory space in Boulder, Colorado, to expand its oligonucleotide manufacturing capabilities and support emerging production technologies for advanced therapeutics.

The new facility will initially focus on enzymatic ligation, a process that uses enzymes to join shorter oligonucleotide fragments into longer therapeutic molecules. Agilent said the approach could complement traditional solid-phase phosphoramidite synthesis and provide greater flexibility depending on a program’s scale and technical requirements.

Through its Advanced Therapeutics Division, Agilent provides development and cGMP manufacturing services for oligonucleotide therapies, including siRNA and antisense oligonucleotides. The Boulder expansion will complement the company’s existing operations in Colorado and broader manufacturing capabilities in Canada.

Agilent expects initial customer programs to begin at the new laboratory in November 2026, subject to operational and regulatory requirements.

The expansion strengthens Agilent’s position in the growing oligonucleotide therapeutics market as drug developers seek more scalable and flexible manufacturing methods for next-generation RNA-based treatments.

💬

The Investor 10-06-26

Agilent Launches NovoStation to Automate Flow Cytometry Sample Preparation

Agilent Technologies launched the NovoStation Sample Preparation System, a new automated platform designed to simplify and standardize flow cytometry sample preparation.

When used with Agilent’s NovoCyte flow cytometers and NovoExpress software, NovoStation creates a connected sample-to-answer workflow that automates reagent cocktailing and sample washing before moving samples directly into data acquisition.

The system is aimed at pharmaceutical, biopharmaceutical, contract research, core laboratory and academic settings where higher sample volumes and increasingly complex assays can make manual preparation time-consuming and variable.

In validation studies, NovoStation reduced hands-on preparation time by more than 90% while maintaining data quality comparable with manual processing. In a 25-color immunophenotyping workflow involving 30 samples, operator time fell to 7.9 minutes from 85.5 minutes manually. In a kappa/lambda light-chain assay, hands-on time declined to 6.8 minutes from 89.4 minutes.

Agilent said the automation can help laboratories improve reproducibility, reduce workflow bottlenecks and standardize procedures across users and sites.

The company will officially unveil NovoStation at the International Clinical Cytometry Society 2026 conference in Miami, running from October 2 through October 6.

💬

Global Finance News 10-02-26

Agilent Launches FDA-Cleared S540MD Digital Pathology Scanner in U.S.

Agilent Technologies (NYSE: A) has launched its S540MD Slide Scanner System in the United States following FDA clearance, expanding the company’s presence in the growing digital pathology market.

The S540MD is a whole-slide imaging system designed for high-volume clinical laboratories. It can hold up to 540 slides and supports continuous loading, automated scanning and advanced tissue detection, helping laboratories digitize pathology workflows at scale.

Agilent Targets AI-Enabled Pathology Growth

The launch comes as pathology laboratories increasingly adopt digital and AI-enabled diagnostic workflows to handle rising sample volumes and improve efficiency.

Agilent said the scanner is intended to integrate digital imaging with its existing pathology expertise and staining workflows. The system is an Agilent-branded version of Hamamatsu’s NanoZoomer S540MD scanner.

The U.S. rollout follows the product’s January 2026 introduction in selected European markets. For Agilent, the FDA-cleared launch expands its clinical diagnostics portfolio and positions the company to benefit from increasing adoption of digital pathology and AI-assisted laboratory workflows.

💬

The Investor 09-04-26

Agilent Launches Compact Cary 635 FTIR Spectrometer for Laboratory Analysis

Agilent Technologies (NYSE: A) announced Tuesday the launch of the Cary 635 FTIR spectrometer, a compact analytical system designed to improve laboratory efficiency while reducing space, training and maintenance requirements.

The Cary 635 uses Fourier transform infrared spectroscopy to analyze solids, liquids, powders and gases. Agilent describes the system as the smallest FTIR instrument in its class, allowing laboratories to deploy it in space-constrained environments or at different points within analytical workflows.

The system incorporates solid ZnSe optical components for improved moisture resistance and durability, while enhanced sensitivity allows lower-concentration samples to be analyzed using smaller sample volumes. A nondynamic interferometer and permanently aligned optics are designed to improve reliability and simplify maintenance.

Agilent has also emphasized ease of use. Its MicroLab software provides step-by-step, picture-guided workflows and color-coded results, allowing less-experienced laboratory personnel to operate the instrument with limited training. The optional DialPath module further simplifies liquid analysis while reducing consumables, cleaning requirements and sample volumes.

The launch expands Agilent’s spectroscopy portfolio as laboratories increasingly seek instruments that combine analytical performance with automation, smaller footprints and lower operating costs. The Cary 635 could strengthen Agilent’s position across pharmaceutical, chemical, materials and other laboratory markets where FTIR analysis is routinely used for identification and quality control.

💬

WS Investor 09-01-26

Agilent Technologies Inc. partnered with OmixAI in a three-year collaboration to advance AI-driven proteomics and precision medicine in South Korea.

The partnership will combine automation and AI to enable large-scale biological data analysis and accelerate biomarker discovery and drug development.

💬

WS Investor 04-14-26

Agilent Technologies announced the opening of a new Customer Experience Center in Mumbai, reinforcing its long-term investment and presence in India.

The facility integrates technology demonstrations, application expertise, and commercial operations, enabling customers across sectors such as pharmaceuticals, biopharma, diagnostics, and environmental testing to engage directly with Agilent’s solutions.

The center is part of Agilent’s broader strategy to expand customer-facing infrastructure globally, supporting laboratories with hands-on learning, collaboration, and advanced analytical capabilities.

Agilent said the move strengthens its role in India’s rapidly growing scientific and regulatory landscape, helping customers modernize operations and accelerate innovation.

💬

Global Finance News 04-03-26

Agilent Technologies announced it will showcase its latest advancements in precision oncology and digital pathology at the USCAP 2026 Annual Meeting in San Antonio.

The company will highlight expanded biomarker testing capabilities, including a new PD-L1 indication for ovarian-related cancers, reinforcing its focus on precision oncology. Agilent will also present end-to-end digital pathology workflows that integrate staining, imaging, and data management to improve laboratory efficiency, reproducibility, and scalability.

Additionally, Agilent emphasized collaborations with ecosystem partners such as Hamamatsu, Proscia, PathAI, and Visiopharm to support interoperable and flexible digital pathology solutions, positioning the company to advance data-driven and fully integrated pathology environments.

💬

Global Finance News 03-19-26

Agilent Technologies (A) announced the launch of Agilent Advanced Therapeutics, a unified contract development and manufacturing organization (CDMO) platform integrating its capabilities across Canada and the United States.

The new platform combines the strengths of BIOVECTRA in Canada and Agilent’s Nucleic Acid Solutions facility in Colorado to provide end-to-end development and manufacturing services for advanced therapeutics.

The offering includes manufacturing and development capabilities for oligonucleotides, microbial fermentation, synthetic chemistry, bioreagents, highly potent APIs and cell line development, enabling customers to move from early discovery through clinical and commercial production with a single partner.

💬

The Investor 03-11-26

Agilent Technologies announced it has agreed to acquire pathology solutions company Biocare Medical in an all-cash deal valued at $950 million.

Biocare specializes in clinical and research pathology tools, including immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions, and offers more than 300 specialized antibodies used in cancer diagnostics. The company generated more than $90 million in revenue in 2025 and has recorded double-digit revenue and profit growth since 2021.

Agilent said the acquisition will expand its pathology and cancer diagnostics portfolio, strengthen its antibody and reagent offerings, and enhance its ability to serve clinical and research laboratories. The transaction is expected to improve Agilent’s growth rate, margins and recurring non-instrument revenue mix, with earnings per share expected to benefit about 12 months after closing. The deal is expected to close by Agilent’s fourth fiscal quarter of 2026, subject to regulatory approvals.

💬

WS Investor 03-09-26

NYSE:AFollow

NYSE:A